Considerations in Utilizing Oligonucleotide-Based Therapeutics to Prevent or Treat HFpEF

Time: 4:45 pm
day: Day One


  • What are the circumstances and performance criteria to justify oligonucleotide use when small molecule inhibitors are clinically available?
  • Assess antisense oligonucleotides, small interfering RNA, and prevalent delivery strategies with their respective strengths and weaknesses
  • Hear best case practices in experimental evaluation of renal and endocrine oligonucleotide therapies